Annovis Bio, INC Form 4 insider transactions

Annovis Bio director Michael Hoffman acquired 76,344 shares of common stock through open market purchases.

Michael B. Hoffman, a Director at Annovis Bio, Inc., acquired 713,800 shares of common stock on April 2, 2026.

Annovis Bio Director Michael B Hoffman acquired 45,000 shares of common stock for approximately $190,000, signaling confidence in the company.

Annovis Bio Director Michael B. Hoffman filed an amended Form 4 to correct reported beneficial ownership totals following multiple common stock purchases.

Annovis Bio, Inc. Director Michael B. Hoffman acquired 39,200 shares of common stock for approximately $159,875 on November 24, 2025.

Annovis Bio, Inc. Director and 10% owner Michael B. Hoffman acquired 20,000 shares of common stock for approximately $70,000 through open market purchases.

Annovis Bio, Inc. Director Michael B. Hoffman acquired 15,000 shares of common stock at $2.11 per share.

Annovis Bio, Inc.'s President and CEO, Maria-Luisa Maccecchini, acquired 97,561 shares of common stock at $2.05 per share, increasing her direct beneficial ownership to 1,212,020 shares.

Annovis Bio, Inc. Director Michael B. Hoffman acquired 975,610 shares of common stock for over $2 million, increasing his beneficial ownership.

Annovis Bio, Inc. Director Claudine Bruck exercised 7,142 stock options at $0.14 per share, increasing her direct common stock holdings to 13,709 shares.

Annovis Bio, Inc. Director Michael B. Hoffman acquired 15,000 shares of common stock through pre-planned transactions.

Annovis Bio Director Michael B. Hoffman acquired 18,645 shares of common stock through multiple transactions.

Annovis Bio, Inc.'s Vice President of Finance, Andrew Walsh, has reported the acquisition of 500 shares of common stock at a price of $2.90 per share.

Annovis Bio, Inc. Director and 10% owner Michael B. Hoffman reported the acquisition of 25,001 shares of common stock, increasing his total beneficial ownership to over 1.6 million shares, as disclosed in a recent SEC Form 4 filing.

Annovis Bio, Inc. Director Reid McCarthy acquired 2,000 shares of common stock at $2.95 per share, increasing his beneficial ownership to 9,305 shares.

Annovis Bio, Inc.'s President and CEO, Maria-Luisa Maccecchini, acquired 46,000 shares of common stock at $3.37 per share, increasing her total beneficial ownership to over 1.1 million shares.

Annovis Bio, Inc. Director and 10% owner Michael B. Hoffman acquired 5,000 shares of common stock at $2.43 per share, signaling increased insider confidence.

Director Mark K. White acquired stock options in Annovis Bio, Inc. through transactions on November 17, 2023, November 27, 2023 and July 1, 2024.

Director Reid McCarthy receives stock options in Annovis Bio, Inc.

Maria-Luisa Maccecchini, President and CEO of Annovis Bio, Inc., reports charitable donations of common stock and the grant of stock options contingent upon shareholder approval of an equity incentive plan amendment.

Director Michael Hoffman receives stock options in Annovis Bio, contingent on shareholder approval of an equity incentive plan amendment.

Director Claudine Bruck reports the acquisition of stock options in Annovis Bio, Inc.